
What smart money is saying about Cogstate Ltd
1 fund in our archive has pitched Cogstate Ltd — most recently Lakehouse Small Companies Fund in February 2026.
Cogstate Limited, a neuroscience technology company, provides computerized cognitive tests and electronic clinical outcome assessment solutions. The company's cognitive services include project management, data management, scientific consulting, statistical analysis, scales procurement, rater training, and monitoring solutions. It operates in Clinical Trials and Healthcare segments. The Clinical Trials segment provides technology and associated services that are used to quantify the effect of diseases and drugs, and devices or other interventions on human subjects participating in clinical trials primarily conducted by pharmaceutical and biotechnology companies. The Healthcare segment provides Cognigram, a system for regular and standardized testing to assist primary care physicians and/or hospitals in the early detection of cognitive decline. As of June 30, 2022, it had participated in approximately 1,800 academic research. Cogstate Limited was incorporated in 1999 and is based in Melbourne, Australia.
Fund coverage · 1 thesis
- Lakehouse Small Companies FundFebruary 2026
Cogstate Ltd is a neurocognitive assessment provider for CNS clinical trials with surging contract wins, growing backlog and channel leverage, positioning it to capture large Phase 3 opportunities.
Read the full thesis
Read every full thesis on Cogstate Ltd
Unlock all 1 thesis — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.
View plans→